Bleomycin-induced hyperpigmentation and hypersensitivity reactions to etoposide and vinblastine in a child with endodermal sinus tumor.
We report a pediatric case who developed bleomycin-induced hyperpigmentation and hypersensitivity reactions to both etoposide and vinblastine while receiving chemotherapy for germ cell tumor. Skin hyperpigmentation related to chemotherapeutic agents has been reported only rarely in pediatric patients. This patient developed a characteristic skin hyperpigmentation which was "flagellate" in appearance. Two features of the hyperpigmentation were noteworthy: development at a low cumulative dose of bleomycin and persistence after cessation of chemotherapy. Additive effect of cisplatinum-induced hyperpigmentation was suggested. Although hypersensitivity reactions to etoposide have been previously reported, hypersensitivity reactions to vinblastine are almost unknown. To our knowledge, this is the first report of hypersensitivity reaction to vinblastine in a child in English literature.
Mutafoğlu-Uysal
K
K
Department of Pediatric Oncology, Dokuz Eylül University Institute of Oncology, Izmir, Turkey.
Sarialioğlu
F
F
Olgun
N
N
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000150:complications*; D018240:Endodermal Sinus Tumor / Q000150:complications*; D005047:Etoposide / Q000276:immunology*; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced / Q000150:complications*; D010051:Ovarian Neoplasms / Q000139:chemically induced / Q000150:complications*; D014747:Vinblastine / Q000276:immunology*
D000970:Antineoplastic Agents; D001761:Bleomycin; D014747:Vinblastine; D005047:Etoposide